How Drug Trials End
Most drug trials never say how they turned out. Of those that do, this shows how many met their main goal, how many missed, and how many stopped early and why, for each disease and drug.
524,548 ClinicalTrials.gov studies, each labelled by how it ended: met its primary endpoint, missed it, or stopped early and why. Most never report a result, so rates here are of the 102,310 whose ending is known.
- Ending known: 102,310
- Met primary endpoint: 44%
- Stopped early: 48%
How Trials End
Trials whose ending is known.
- Met its primary endpoint44,97844%
- Missed its primary endpoint8,3218%
- Stopped: lack of efficacy3,2103%
- Stopped: safety6431%
- Stopped: enrollment or feasibility10,97511%
- Stopped: sponsor or business decision4,7495%
- Stopped: funding1,7972%
- Stopped: other or unclear27,63727%
Why Trials Stop
The reason the sponsor gave, where it fits one of these.
- Enrollment or feasibility10,975
- Sponsor or business decision4,749
- Lack of efficacy3,210
- Funding1,797
- Safety643
Hardest Diseases
Lowest share of trials meeting their endpoint, of 300 or more with a known ending.
- Glioblastomaof 46619%
- Brain cancerof 38919%
- Bone fractureof 38920%
- Sarcomaof 34320%
- Respiratory distress syndromeof 32820%
- Squamous cell cancer of head and neckof 33220%
- Pancreatic cancerof 63821%
- Adenocarcinomaof 56323%
- Squamous cell carcinomaof 45225%
- Head and neck cancerof 43025%
Most Missed Endpoints
FDA-approved drugs with the most trials that missed their primary endpoint, often in new uses.
Every Condition and Drug
Most trials first; conditions with 20 or more known endings, drugs with 10 or more1,079 of 1,079 conditions
| Breast cancer | 11,325 | 851 | 210 | 1,413 | 34% | 112 |
| Diabetes mellitus | 10,779 | 1,757 | 181 | 791 | 64% | 61 |
| Type 2 diabetes | 8,392 | 1,521 | 92 | 619 | 68% | 43 |
| COVID-19 | 7,561 | 395 | 176 | 913 | 27% | 76 |
| Lung cancer | 7,223 | 465 | 196 | 1,097 | 26% | 114 |
| Depression | 7,138 | 820 | 172 | 594 | 52% | 34 |
| Leukemia | 6,435 | 608 | 86 | 1,152 | 33% | 117 |
| Lymphoma | 6,428 | 661 | 82 | 1,031 | 37% | 87 |
| Hypertension | 6,356 | 777 | 108 | 638 | 51% | 51 |
| Stroke | 6,163 | 413 | 105 | 458 | 42% | 33 |
| Prostate cancer | 5,809 | 366 | 122 | 833 | 28% | 85 |
| Non-small cell lung cancer | 5,613 | 405 | 154 | 955 | 27% | 97 |
| Depressive disorder | 5,594 | 692 | 144 | 508 | 51% | 28 |
| Coronary artery disease | 5,323 | 546 | 119 | 425 | 50% | 19 |
| Heart failure | 5,179 | 463 | 150 | 655 | 37% | 49 |
| Colorectal cancer | 4,766 | 330 | 122 | 510 | 34% | 46 |
| Osteoarthritis | 4,555 | 407 | 74 | 388 | 47% | 26 |
| HIV infection | 4,305 | 593 | 113 | 313 | 58% | 31 |
| Obesity | 4,071 | 393 | 53 | 222 | 59% | 12 |
| Postoperative pain | 4,051 | 296 | 70 | 317 | 43% | 27 |
| Parkinson's disease | 3,950 | 275 | 39 | 334 | 42% | 29 |
| Arthritis | 3,882 | 648 | 69 | 384 | 59% | 42 |
| Sclerosis | 3,765 | 350 | 80 | 413 | 42% | 44 |
| Asthma | 3,658 | 508 | 109 | 321 | 54% | 34 |
| Hepatitis | 3,626 | 631 | 60 | 397 | 58% | 37 |
| Chronic obstructive pulmonary disease (COPD) | 3,551 | 537 | 87 | 289 | 59% | 14 |
| Fibrosis | 3,487 | 322 | 80 | 379 | 41% | 45 |
| Atrial fibrillation | 3,474 | 333 | 60 | 327 | 46% | 20 |
| Multiple myeloma | 3,427 | 339 | 36 | 594 | 35% | 59 |
| Myocardial ischemia | 3,407 | 362 | 82 | 249 | 52% | 12 |
| Alzheimer's disease | 3,271 | 193 | 84 | 352 | 31% | 59 |
| Cognitive dysfunction | 3,264 | 168 | 51 | 230 | 37% | 17 |
| Schizophrenia | 3,255 | 403 | 79 | 309 | 51% | 31 |
| Type 1 diabetes | 3,244 | 413 | 50 | 276 | 56% | 23 |
| Multiple sclerosis | 3,166 | 300 | 52 | 314 | 45% | 25 |
| Hemorrhage | 3,112 | 243 | 79 | 300 | 39% | 22 |
| Myeloid leukemia | 3,076 | 306 | 51 | 572 | 33% | 63 |
| Anxiety disorder | 2,985 | 282 | 38 | 174 | 57% | 8 |
| Knee osteoarthritis | 2,972 | 263 | 42 | 212 | 51% | 12 |
| Coronary disease | 2,963 | 307 | 65 | 201 | 54% | 10 |
| Hepatitis a | 2,938 | 531 | 55 | 319 | 59% | 28 |
| Infarction | 2,897 | 261 | 126 | 243 | 41% | 16 |
| Plasma cell cancer | 2,879 | 301 | 34 | 506 | 36% | 49 |
| Obstructive lung disease | 2,861 | 409 | 74 | 246 | 56% | 9 |
| Overweight | 2,785 | 338 | 53 | 143 | 63% | 6 |
| Pancreatic cancer | 2,776 | 133 | 77 | 428 | 21% | 44 |
| Melanoma | 2,747 | 227 | 65 | 513 | 28% | 57 |
| Hepatocellular carcinoma | 2,724 | 145 | 47 | 334 | 28% | 29 |
| Myocardial infarction | 2,718 | 251 | 119 | 216 | 43% | 10 |
| Chronic renal insufficiency | 2,714 | 254 | 58 | 253 | 45% | 11 |
Outcome labels are from TrialPanorama (Apache-2.0), built from ClinicalTrials.gov records partly automatically, so some are wrong: in a sample of trials labelled stopped for lack of efficacy, about a quarter gave another reason. Met and missed come from posted results and publications, which favour trials that succeeded. Stopped-early reasons are the sponsor's own words, grouped; โother or unclearโ is left out of the reasons chart. Conditions are MeSH terms; a trial counts under each condition and drug it names. TrialPanorama